OIS at AAO 2015

ONL Therapeutics

Nov 12, 2015 12:21pm ‐ Nov 12, 2015 12:29pm


Description

ONL is committed to protecting and improving the vision of patients with retinal diseases and conditions, including retinal detachment and dry age-related macular degeneration (AMD). ONL is the first and only company focused on preventing the death of photoreceptors, the leading cause of blindness and a completely unaddressed medical need.

Speaker(s):

You must be logged in and own this session in order to post comments.

Print Certificate
Review Answers
Print Transcript
Completed on: token-completed_on
Review Answers
Please select the appropriate credit type:
/
test_id: 
credits: 
completed on: 
* - Indicates answer is required.
token-content
token-index
token-content
token-index
token-content
token-index
token-content
token-index
token-content
token-index
token-content
token-index
token-content
/
/
token-index
token-content